Diamedica Therapeutics Inc.
- Address
- 301 Carlson Parkway Suite 210
Sponsor Overview
Specializations
Neurology and Stroke Care
Diamedica Therapeutics Inc. focuses on clinical research in acute ischemic stroke, with attention to patients presenting after the onset of neurological injury and those with moderate stroke severity.
- Acute ischemic stroke
- Neurological deficit
- Moderate stroke severity
The sponsor’s research interest is centered on stroke populations with limited treatment options, particularly cases involving small vessel and medium vessel occlusions.
Cerebrovascular Disease
The trial portfolio reflects a therapeutic interest in cerebrovascular disease, especially conditions where restoring blood flow and preserving brain function remain central clinical concerns.
- Small vessel occlusion
- Medium vessel occlusion
- Brain ischemia
Research activity is directed toward patients who may not be candidates for mechanical thrombectomy, highlighting a focus on unmet needs within stroke care.
Acute Neurologic Intervention
Diamedica Therapeutics Inc. is engaged in research relevant to early treatment after stroke onset, including patients assessed within a short time window after symptom presentation or last known normal status.
- Early stroke presentation
- Time-sensitive neurological care
- Persistent neurological deficit
The clinical focus includes individuals who remain symptomatic after standard acute care measures, supporting investigation in difficult-to-treat stroke scenarios.
Reperfusion and Standard Stroke Therapy
The sponsor’s research landscape includes patients in whom established acute ischemic stroke therapies, such as fibrinolytics and mechanical thrombectomy, are considered in routine care.
- Fibrinolytic therapy
- Mechanical thrombectomy
- Standard of care stroke treatment
This places the therapeutic emphasis on stroke management pathways where additional options may be needed alongside conventional reperfusion strategies.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) |  Belgium France Hungary Poland Romania Spain | Recruiting |
Data & Insights
This sponsor works with 0 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 33 sites across their trial portfolio.
Therapeutic Focus
- 1.Nervous System Diseases1 trial449 other sponsors
Partnered Research Centres
33 centres- Address
- Ul. Rudolfa Weigla 5, 53-114 Wroclaw
- Address
- President Kennedylaan 4, 8500 Kortrijk
- Address
- 264 Rue Saint Pierre, 13005 Marseille
- Address
- Maglodi Ut 89-91, Kerulet, 1106 Budapest
- Address
- Szentpeteri Kapu 72-76, 3526 Miskolc
- Address
- 16 Boulevard De Bulgarie, Bp 90349, 35200 Rennes
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Diamedica Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.